CommercialDocumentationMedium impact
08.00.90t, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
This policy update modifies the medical necessity criteria for Paclitaxel Protein-Bound Particles (Abraxane) injectable suspension. The billing team must review updated clinical guidelines and prior authorization requirements to ensure claims comply with the new medical necessity standards effective immediately.
Action Required
By July 28, 2025: Billing and prior authorization teams must review the updated medical necessity criteria for HCPCS code J9264 (Paclitaxel protein-bound particles) in policy 08.00.90t and update all prior authorization templates, denial reason codes, and claim validation logic accordingly. Notify oncology providers of any new documentation or clinical criteria requirements. Verify that claims submitted after the effective date include all required medical necessity documentation per the new policy. Claims submitted without compliance to updated criteria may be denied.